Zoetis Inc (NYSE:ZTS) insider Heidi C. Chen sold 15,710 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $95.49, for a total transaction of $1,500,147.90. Following the transaction, the insider now owns 13,963 shares of the company’s stock, valued at approximately $1,333,326.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Zoetis stock opened at $96.20 on Friday. Zoetis Inc has a 12-month low of $77.00 and a 12-month high of $97.95. The stock has a market capitalization of $46.23 billion, a PE ratio of 30.73, a PEG ratio of 1.74 and a beta of 0.92. The company has a current ratio of 3.60, a quick ratio of 2.46 and a debt-to-equity ratio of 2.95.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 14th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.02. Zoetis had a net margin of 24.51% and a return on equity of 73.85%. The firm had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same period in the prior year, the firm posted $0.69 earnings per share. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. On average, analysts anticipate that Zoetis Inc will post 3.46 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Monday, June 3rd. Stockholders of record on Thursday, April 18th will be issued a $0.164 dividend. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date of this dividend is Wednesday, April 17th. Zoetis’s payout ratio is 21.09%.
A number of equities analysts have weighed in on the stock. Stifel Nicolaus upgraded shares of Zoetis from a “hold” rating to a “buy” rating and increased their target price for the stock from $97.00 to $110.00 in a research report on Monday, March 4th. Zacks Investment Research upgraded shares of Zoetis from a “sell” rating to a “hold” rating in a research report on Saturday, February 16th. BMO Capital Markets increased their target price on shares of Zoetis from $93.00 to $101.00 and gave the stock a “market perform” rating in a research report on Monday, February 25th. Finally, UBS Group assumed coverage on shares of Zoetis in a research report on Wednesday, January 23rd. They set a “neutral” rating and a $86.00 target price for the company. Five equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $98.85.
Several institutional investors have recently made changes to their positions in the company. Van Leeuwen & Company LLC lifted its holdings in shares of Zoetis by 407.5% in the fourth quarter. Van Leeuwen & Company LLC now owns 22,869 shares of the company’s stock worth $1,956,000 after buying an additional 18,363 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Zoetis by 9.9% in the fourth quarter. American Century Companies Inc. now owns 4,025,622 shares of the company’s stock worth $344,352,000 after buying an additional 361,983 shares in the last quarter. Sowell Financial Services LLC lifted its holdings in shares of Zoetis by 7.5% in the fourth quarter. Sowell Financial Services LLC now owns 5,064 shares of the company’s stock worth $433,000 after buying an additional 352 shares in the last quarter. Fulcrum Equity Management purchased a new stake in shares of Zoetis in the fourth quarter worth about $841,000. Finally, Norges Bank purchased a new stake in shares of Zoetis in the fourth quarter worth about $404,080,000. 89.98% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4222613/heidi-c-chen-sells-15710-shares-of-zoetis-inc-zts-stock.html.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: How is the LIBOR rate calculated?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.